Abstract

In support of vaccine development, we develop, optimize, and validate assays to monitor immunogenicity of candidate vaccines. In addition, we maintain good laboratory practices to assure data consistency and accuracy in support of regulatory filings. In order to have the most relevant assays of immunogenicity, we continually develop, optimize, and validate new assays to monitor vaccine immunogenicity of vaccines, and develop and institute immunogenicity criteria for vaccine lot release by establishing lot release criteria in animal vaccination studies.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI005073-02
Application #
7184290
Study Section
(VRC)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2005
Total Cost
Indirect Cost

  Institution

Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Adams, William C; Bond, Emily; Havenga, Menzo J E et al. (2009) Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. J Gen Virol 90:1600-10
Koup, Richard A; Lamoreaux, Laurie; Zarkowsky, David et al. (2009) Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol 83:6318-22
Parrino, Janie; McCurdy, Lewis H; Larkin, Brenda D et al. (2007) Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25:1513-25
Precopio, Melissa L; Betts, Michael R; Parrino, Janie et al. (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204:1405-16
Catanzaro, Andrew T; Roederer, Mario; Koup, Richard A et al. (2007) Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25:4085-92
Beveridge, Natalie E R; Price, David A; Casazza, Joseph P et al. (2007) Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37:3089-100
Tavel, Jorge A; Martin, Julie E; Kelly, Grace G et al. (2007) Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 44:601-5
Martin, Julie E; Pierson, Theodore C; Hubka, Sarah et al. (2007) A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196:1732-40
Graham, Barney S; Koup, Richard A; Roederer, Mario et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194:1650-60
Martin, Julie E; Sullivan, Nancy J; Enama, Mary E et al. (2006) A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13:1267-77

Showing the most recent 10 out of 18 publications